Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can meal timing protect your brain during cancer treatment?

NCT ID NCT06315296

Symptom relief Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a text-message-based diet program called Txt4fasting for people with breast or lung cancer that spread to the brain. The goal was to see if eating only during certain hours could reduce thinking and memory problems after radiation. Only 1 person enrolled before the study was stopped, so we don't have enough data to know if it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1 person

The number who actually took part.

Started

Dec 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Pathologically proven breast or lung cancer primary malignancy confirmed * Body mass index (BMI) ≥ 25 kg/m\^2 * SRS candidate (1-10 MRI detected brain metastases as per the discretion of radiologist) as determined by the treating physician * Chemotherapy, hormone, and immune therapy will be allowed concurrently * Willing and able to comply with the protocol for the duration of the study * Able to speak, read and write English * Negative pregnancy test if childbearing potential * Owns a mobile phone with mobile text messaging (TXT) capability Exclusion Criteria: * Inability to tolerate a normal diet (may include an active malabsorption syndrome at the time of consent \[i.e. Crohn's disease, major bowel resection leading to permanent malabsorption\]) * Not a SRS candidate as determined by the treating physician * Prior brain surgery ≤ 14 days prior to enrollment * Intractable seizures while on adequate anticonvulsant therapy-more than 1 seizure per week for the past 2 months * Patient with a diagnosis of glioma, or other World Health Organization (WHO) grade II-IV primary brain tumor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anatomic stage IV breast cancer ajcc V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast carcinoma breast neoplasm lung cancer lung neoplasm metastatic carcinoma metastatic malignant neoplasm metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anatomic stage IV breast cancer ajcc V8 Metastatic breast carcinoma Metastatic lung carcinoma Metastatic malignant neoplasm in the brain Stage IV lung cancer ajcc V8

Contacts and locations

Locations

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.